Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Oncology

Staying Vigilant: Survivorship and Your Surveillance Plan

At a Glance

The first two to three years after Merkel cell carcinoma treatment carry the highest risk of recurrence. A standard surveillance plan involves physical exams, imaging scans, and specific blood tests every 3 to 6 months to detect any return of the cancer as early as possible.

Completing treatment for Merkel cell carcinoma (MCC) is a major milestone, but it also marks the beginning of a critical new phase: surveillance. Because MCC is aggressive, the risk of it returning is highest in the first two to three years after diagnosis [1][2]. Vigilant monitoring during this window is the most effective way to catch any recurrence early, when it is most treatable.

The Surveillance Schedule

While every plan is tailored to the individual, most experts follow a schedule that is front-loaded during the first few years.

  • Physical Exams: For the first 2–3 years, you will likely see your oncologist or dermatologist every 3 to 6 months [3][4]. These visits include a thorough “head-to-toe” skin check and a manual exam of your lymph nodes (checking for swelling in the neck, armpits, and groin) [3][5].
  • Imaging (Scans): Depending on your stage and risk factors (such as a weakened immune system), your doctor may order PET/CT or CT scans every 3 to 6 months for the first several years [3][6].
  • Blood Tests: If your tumor was virus-positive, your doctor may use the MCPyV oncoprotein antibody test (sometimes called the AMSET or AMES test). A rising level of these antibodies in your blood can sometimes signal a recurrence months before it shows up on a scan [7][8].

Where and When Does It Return?

MCC can recur in three main ways:

  1. Local Recurrence: The cancer returns at or near the original site in the skin [9].
  2. Regional Recurrence: The cancer appears in the nearby lymph nodes [2][10].
  3. Distant Metastasis: The cancer spreads to other organs, most commonly the liver, lungs, or bones [11][12].

Approximately 90% of recurrences occur within the first three years, which is why the frequency of your appointments will typically decrease after you pass that mark [1][3].

Managing “Scanxiety”

It is completely normal to feel intense anxiety before and after your surveillance scans—a phenomenon often called scanxiety [13][14].

  • Acknowledge the stress: Recognize that this feeling is a legitimate clinical concern shared by many patients [15][16].
  • Speed up the results: Ask your care team about their policy for releasing results. Minimizing the “waiting period” is one of the most effective ways to reduce distress [17][18].
  • Plan your distraction: Schedule scans for earlier in the week so you aren’t waiting over a weekend, and plan an engaging activity for the days leading up to your results [19][20].

Your Role: Self-Monitoring

Between doctor visits, you are the most important member of your surveillance team.

  • Monthly Skin/Node Checks: Perform a monthly self-exam. Look for any new, firm, painless lumps on the skin or any swelling in your lymph node areas [2][21].
  • Lifestyle Protection: Since UV radiation is a driver for many MCC cases, protecting your skin from further sun damage is essential [22][23]. Wear sun-protective clothing (UPF 50+) and apply broad-spectrum sunscreen daily [24].
  • Report Changes Immediately: If you find a new nodule or experience persistent new symptoms (like unexplained bone pain or weight loss), do not wait for your next scheduled appointment. Contact your oncology team right away [21][25].

Common questions in this guide

How often will I need scans and physical exams after MCC treatment?
During the first two to three years, you will typically need physical exams and imaging, such as PET/CT scans, every three to six months. This front-loaded schedule helps catch any potential recurrence early when it is most treatable.
What is the MCPyV antibody blood test used for?
If your Merkel cell carcinoma was virus-positive, this blood test measures your MCPyV oncoprotein antibodies. A rising level of these antibodies can sometimes signal that the cancer is returning months before it appears on an imaging scan.
What are the signs that Merkel cell carcinoma has returned?
Signs of recurrence include new, firm, painless lumps on the skin or swelling in the lymph nodes of your neck, armpits, or groin. If the cancer has spread to other organs, you might experience unexplained bone pain or unexpected weight loss.
How can I cope with scanxiety during my surveillance period?
Scanxiety is a very normal response to post-treatment monitoring. You can manage this stress by asking your doctor about their policy for releasing scan results quickly, scheduling scans early in the week to avoid weekend waiting, and planning distracting activities.
What should I do if I find a new lump between scheduled appointments?
If you discover a new nodule, swollen lymph node, or persistent new symptoms between your regular check-ups, do not wait for your next appointment. You should contact your oncology team immediately for an evaluation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific surveillance schedule for me: how often will I have physical exams, and how often will I have scans?
  2. 2.Am I a candidate for the Merkel cell polyomavirus (MCPyV) antibody blood test, and how often should we check it?
  3. 3.If I find a new lump or skin change between my scheduled appointments, who is my immediate point of contact?
  4. 4.Which imaging tests (PET/CT, CT, or MRI) are most appropriate for monitoring my specific stage and tumor location?
  5. 5.What is the policy for releasing my scan results to the patient portal, and can we schedule a call to discuss them right away?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases.

    Rusheen J, Clune J, Ariyan S, et al.

    Frontiers in oncology 2023; (13()):1217816 doi:10.3389/fonc.2023.1217816.

    PMID: 37476373
  2. 2

    Merkel cell carcinoma with seborrheic keratosis: A unique association.

    Anand MS, Krishnamurthy S, Ravindranath S, Ranganathan J

    Indian journal of pathology & microbiology 2018; (61(1)):101-102 doi:10.4103/IJPM.IJPM_659_16.

    PMID: 29567894
  3. 3

    Management Recommendations for Merkel Cell Carcinoma-A Danish Perspective.

    Naseri S, Steiniche T, Ladekarl M, et al.

    Cancers 2020; (12(3)) doi:10.3390/cancers12030554.

    PMID: 32121063
  4. 4

    Merkel Cell Carcinoma: Updates on Staging and Management.

    Cornejo C, Miller CJ

    Dermatologic clinics 2019; (37(3)):269-277 doi:10.1016/j.det.2019.03.001.

    PMID: 31084721
  5. 5

    Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

    Bichakjian CK, Olencki T, Aasi SZ, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(6)):742-774 doi:10.6004/jnccn.2018.0055.

    PMID: 29891526
  6. 6

    Merkel Cell Carcinoma Analysis of Outcomes: A 30-Year Experience.

    Liang E, Brower JV, Rice SR, et al.

    PloS one 2015; (10(6)):e0129476 doi:10.1371/journal.pone.0129476.

    PMID: 26053480
  7. 7

    Merkel Cell Carcinoma.

    Lewis DJ, Sobanko JF, Etzkorn JR, et al.

    Dermatologic clinics 2023; (41(1)):101-115 doi:10.1016/j.det.2022.07.015.

    PMID: 36410971
  8. 8

    Merkel cell carcinoma in the hand. Report of two cases.

    Mesa F, Cardona M, Mesa C, et al.

    Case reports in plastic surgery & hand surgery 2022; (9(1)):41-45 doi:10.1080/23320885.2021.2025378.

    PMID: 35083368
  9. 9

    Merkel cell carcinoma incidence is increasing in Sweden.

    Zaar O, Gillstedt M, Lindelöf B, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2016; (30(10)):1708-1713 doi:10.1111/jdv.13698.

    PMID: 27136306
  10. 10

    Merkel cell carcinoma.

    Mistry K, Levell NJ, Craig P, et al.

    Skin health and disease 2021; (1(4)):e55 doi:10.1002/ski2.55.

    PMID: 35663768
  11. 11

    A Rare Case of Rapidly Progressing Merkel Cell Carcinoma.

    Jain DST, Riyadh O, Tran K, et al.

    Cureus 2025; (17(7)):e88816 doi:10.7759/cureus.88816.

    PMID: 40873822
  12. 12

    A Rare Cause of Acute Liver Failure: Diffuse Liver Metastization of Merkel Cell Carcinoma.

    Santos AL, Magno Pereira V, Coelho R, et al.

    GE Portuguese journal of gastroenterology 2020; (27(3)):203-206 doi:10.1159/000503150.

    PMID: 32509927
  13. 13

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  14. 14

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  15. 15

    Scanxiety Conversations on Twitter: Observational Study.

    Bui KT, Li Z, Dhillon HM, et al.

    JMIR cancer 2023; (9()):e43609 doi:10.2196/43609.

    PMID: 37074770
  16. 16

    Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

    Hussain M, Chau S, Turner M, Paterson C

    Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

    PMID: 37735038
  17. 17

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  18. 18

    Qualitative study: patients' and parents' views on brain tumour MRIs.

    Tyldesley-Marshall N, Greenfield S, Neilson S, et al.

    Archives of disease in childhood 2020; (105(2)):166-172 doi:10.1136/archdischild-2019-317306.

    PMID: 31391153
  19. 19

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  20. 20

    Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.

    King AL, Acquaye-Mallory AA, Vera E, et al.

    BMC cancer 2023; (23(1)):262 doi:10.1186/s12885-023-10671-2.

    PMID: 36944930
  21. 21

    S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022.

    Becker JC, Beer AJ, DeTemple VK, et al.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2023; (21(3)):305-320 doi:10.1111/ddg.14930.

    PMID: 36929552
  22. 22

    Modern diagnostics and treatment of Merkel cell carcinoma.

    Weilandt J, Peitsch WK

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2023; (21(12)):1524-1546 doi:10.1111/ddg.15214.

    PMID: 37875785
  23. 23

    A Comparative Study of Merkel Cell Carcinoma and Melanoma Incidence and Survival in the United States, 2000-2021.

    Tribble JT, Brownell I, Cahoon EK, et al.

    The Journal of investigative dermatology 2025; (145(8)):1979-1986.e3 doi:10.1016/j.jid.2024.12.014.

    PMID: 39778651
  24. 24

    Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.

    Blackmon JT, Dhawan R, Viator TM, et al.

    JAAD case reports 2017; (3(3)):185-189 doi:10.1016/j.jdcr.2017.02.003.

    PMID: 28443305
  25. 25

    Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma.

    Wang SY, Turner G, Valdes-Morales KL, et al.

    JAMA otolaryngology-- head & neck surgery 2026; (152(3)):313-322 doi:10.1001/jamaoto.2025.5211.

    PMID: 41609724

This page provides general information about Merkel cell carcinoma survivorship and surveillance. Always consult your oncology team to establish a personalized monitoring schedule tailored to your risk factors.

Get notified when new evidence is published on Cutaneous neuroendocrine carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.